Zhejiang Huakang Pharmaceutical Co Ltd (605077) — Capital Reinvestment Ratio
Zhejiang Huakang Pharmaceutical Co Ltd (605077) has a Capital Reinvestment Ratio of 9.76x as of December 2024, meaning it reinvests 10% of its operating cash flow (CN¥146.50 Million) in capital expenditures (CN¥1.43 Billion). Check Zhejiang Huakang Pharmaceutical Co Ltd tangible equity quality to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Zhejiang Huakang Pharmaceutical Co Ltd Capital Reinvestment Ratio (2016–2024)
This chart tracks Zhejiang Huakang Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 9 annual periods. For the full cash flow conversion analysis, see cash flow conversion of Zhejiang Huakang Pharmaceutical Co Ltd.
Annual Capital Reinvestment Ratio for Zhejiang Huakang Pharmaceutical Co Ltd (2016–2024)
Year-by-year Capital Reinvestment Ratio for Zhejiang Huakang Pharmaceutical Co Ltd from 2016 to 2024. See 605077 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 9.76x | CN¥146.50 Million | CN¥1.43 Billion | ▲ +775.3% |
| 2023 | 1.11x | CN¥619.47 Million | CN¥690.70 Million | ▼ -43.8% |
| 2022 | 1.98x | CN¥271.98 Million | CN¥539.75 Million | ▲ +45.3% |
| 2021 | 1.37x | CN¥264.32 Million | CN¥360.93 Million | ▲ +81.0% |
| 2020 | 0.75x | CN¥335.24 Million | CN¥252.95 Million | ▲ +60.5% |
| 2019 | 0.47x | CN¥281.31 Million | CN¥132.21 Million | ▼ -45.4% |
| 2018 | 0.86x | CN¥140.97 Million | CN¥121.38 Million | ▲ +320.6% |
| 2017 | 0.20x | CN¥80.56 Million | CN¥16.49 Million | ▼ -24.8% |
| 2016 | 0.27x | CN¥93.02 Million | CN¥25.32 Million | — |